Actavis U.S., the United States manufacturing and marketing division of the international generic pharmaceutical company Actavis Group, on Friday announced plans to consolidate all New Jersey manufacturing operations at its Elizabeth, N.J. facility, a move that will enhance the leading generic manufacturer’s efficiency and focus.

“As a company, we are constantly evolving and seeking ways to improve operational and other efficiencies that will enhance our competitiveness,” said Actavis Inc. CEO Doug Boothe. “Consolidating our New Jersey operations at our Elizabeth site will help us achieve significant savings to allow us to continue delivering best value pharmaceuticals at competitive prices to our customers. Ultimately, this will benefit U.S. consumers.”

The company will cease its current operations in Passaic County, with some employees transferring to Elizabeth or other Actavis sites. Others will be let go beginning in May. Employees were notified of the company’s plans today.

“This was not an easy decision, especially in its impact on these valued employees,” Boothe said. “But it was determined that continuing to operate those facilities did not align with our long-term strategy and, as such, would not be in the best interest of Actavis, our employees or our customers.”

Enquiries
Media Line
for Actavis U.S.
Tel: +1 973 889-6689
E-mail: media@actavis.com